Reverse Transcriptase Inhibitors

Antiviral Agents
A 2-Hydroxyisoquinoline-1,3-Dione Active-Site RNase H Inhibitor Binds in Multiple Modes to HIV-1 Reverse Transcriptase
Karen A. Kirby, Nataliya A. Myshakina, Martin T. Christen, Yue-Lei Chen, Hilary A. Schmidt, Andrew D. Huber, Zhaoyong Xi, Seongmi Kim, Rohit K. Rao, Skyler T. Kramer, Qiongying Yang, Kamalendra Singh, Michael A. Parniak, Zhengqiang Wang, Rieko Ishima, Stefan G. Sarafianos
Antiviral Agents
MK-8591 (4′-Ethynyl-2-Fluoro-2′-Deoxyadenosine) Exhibits Potent Activity against HIV-2 Isolates and Drug-Resistant HIV-2 Mutants in Culture
Vincent H. Wu, Robert A. Smith, Sara Masoum, Dana N. Raugi, Selly Ba, Moussa Seydi, Jay A. Grobler, Geoffrey S. Gottlieb
and for the University of Washington–Dakar HIV-2 Study Group
Antiviral Agents
Structural Insights into HIV Reverse Transcriptase Mutations Q151M and Q151M Complex That Confer Multinucleoside Drug Resistance
Kalyan Das, Sergio E. Martinez, Eddy Arnold
Antiviral Agents
Low Frequency of Intermittent HIV-1 Semen Excretion in Patients Treated with Darunavir-Ritonavir at 600/100 Milligrams Twice a Day plus Two Nucleoside Reverse Transcriptase Inhibitors or Monotherapy
Sidonie Lambert-Niclot, Gilles Peytavin, Claudine Duvivier, Catherine Poirot, Michèle Algarte-Genin, Sophie Pakianather, Jean-Luc Meynard, Marc-Antoine Valantin, Jean-Michel Molina, Philippe Flandre, Christine Katlama, Vincent Calvez, Anne-Geneviève Marcelin
Antiviral Agents
Mechanisms Involved in the Selection of HIV-1 Reverse Transcriptase Thumb Subdomain Polymorphisms Associated with Nucleoside Analogue Therapy Failure
Gilberto Betancor, Maria C. Puertas, María Nevot, César Garriga, Miguel A. Martínez, Javier Martinez-Picado, Luis Menéndez-Arias
Antiviral Agents
Distinct Mutation Pathways of Non-Subtype B HIV-1 during In Vitro Resistance Selection with Nonnucleoside Reverse Transcriptase Inhibitors
Ming-Tain Lai, Meiqing Lu, Peter J. Felock, Renee C. Hrin, Ying-Jie Wang, Youwei Yan, Sanjeev Munshi, Georgia B. McGaughey, Robert M. Tynebor, Thomas J. Tucker, Theresa M. Williams, Jay A. Grobler, Daria J. Hazuda, Philip M. McKenna, Michael D. Miller
Antiviral Agents
In Vitro Mitochondrial Toxicity of Metacavir, a New Nucleoside Reverse Transcriptase Inhibitor for Treatment of Hepatitis B Virus
Pinghu Zhang, Luyong Zhang, Zhenzhou Jiang, Tao Wang, Hongkui Chen, Yating Xiong, Zhan Li
Antiviral Agents
Lersivirine, a Nonnucleoside Reverse Transcriptase Inhibitor with Activity against Drug-Resistant Human Immunodeficiency Virus Type 1
Romuald Corbau, Julie Mori, Chris Phillips, Lesley Fishburn, Alex Martin, Charles Mowbray, Wendy Panton, Caroline Smith-Burchnell, Adele Thornberry, Heather Ringrose, Thorsten Knöchel, Steve Irving, Mike Westby, Anthony Wood, Manos Perros
Pharmacology
Phase 2a Randomized Controlled Trial of Short-Term Activity, Safety, and Pharmacokinetics of a Novel Nonnucleoside Reverse Transcriptase Inhibitor, RDEA806, in HIV-1-Positive, Antiretroviral-Naïve Subjects
Graeme Moyle, Marta Boffito, Albrecht Stoehr, Armin Rieger, Zancong Shen, Kimberly Manhard, Beth Sheedy, Vijay Hingorani, Anneke Raney, Mai Nguyen, Tranh Nguyen, Voon Ong, Li-Tain Yeh, Barry Quart
Pharmacology
Importance of Serum Concentration of Adefovir for Lamivudine-Adefovir Combination Therapy in Patients with Lamivudine-Resistant Chronic Hepatitis B
Fukiko Mitsui, Masataka Tsuge, Takashi Kimura, Shosuke Kitamura, Hiromi Abe, Hiromi Saneto, Tomokazu Kawaoka, Daiki Miki, Tsuyoshi Hatakeyama, Nobuhiko Hiraga, Michio Imamura, Yoshiiku Kawakami, Hiroshi Aikata, Shoichi Takahashi, C. Nelson Hayes, Harue Igarashi, Kentaro Morimoto, Masao Shimizu, Kazuaki Chayama

Main menu

User menu

Search

Reverse Transcriptase Inhibitors

Pages